# A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers

> **NCT04892875** · PHASE1 · WITHDRAWN · sponsor: **Jennifer Choe**

## Conditions studied

- Head and Neck Cancer
- Squamous Cell Carcinoma of Head and Neck
- Oral Cavity Squamous Cell Carcinoma
- Oral Cavity Cancer
- Oropharynx Cancer
- Oropharynx Squamous Cell Carcinoma
- Larynx Cancer
- Pharynx Cancer
- Hypopharynx Cancer
- Hypopharynx Squamous Cell Carcinoma

## Interventions

- **DRUG:** Zimberelimab
- **DRUG:** Etrumadenant
- **DRUG:** Cisplatin
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT04892875
- **Lead sponsor:** Jennifer Choe
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-12-31
- **Primary completion:** 2025-12
- **Final completion:** 2026-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding
- **Last updated:** 2023-11-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04892875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04892875, "A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04892875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*